PDF(Pubmed)
Abstract：
To compare short-term anatomical outcomes observed in optical coherence tomography (OCT) between intravitreal injection (IVI) with anti-vascular endothelial growth factor (VEGF) agent aflibercept (IVA) and subthreshold micropulse laser (SML) therapy in chronic central serous chorioretinopathy (cCSC).
Thirty-nine eyes of 36 patients with symptomatic cCSC in this retrospective study received either IVA or SML between December 2020 and August 2022. Spectral-domain-OCT (SD-OCT) findings were compared between the two treatment groups in terms of central macular thickness (CMT), serous subretinal fluid (SRF) height, the presence of pigment epithelial detachment (PED) and subretinal hyperreflective foci (HF) at baseline and one-month follow-up visits.
Both groups showed significant reductions in CMT and SRF at one-month follow-up visit. However, there were no statistically significant differences between the IVA and SML groups. Complete SRF resolution was observed in 10 out of 21 and 7 out of 18 eyes in the IVA and SML groups, respectively; however, retinal pigment epithelial (RPE) damage remained persistent in patients with PEDs at baseline.
Both IVA and SML were effective in treating cCSC. IVA and SML treatments had comparable effects in reducing CMT and SRF in eyes with cCSC. Further prospective studies with larger sample sizes and long-term follow-up visits are warranted to identify the long-term efficacy.
cCSC lead to subsequent irreversible photoreceptor damage and visual complaints.IVA and SML treatments have comparable effects in reducing CMT and SRF in cCSC eyes.
Thirty-nine eyes of 36 patients with symptomatic cCSC in this retrospective study received either IVA or SML between December 2020 and August 2022. Spectral-domain-OCT (SD-OCT) findings were compared between the two treatment groups in terms of central macular thickness (CMT), serous subretinal fluid (SRF) height, the presence of pigment epithelial detachment (PED) and subretinal hyperreflective foci (HF) at baseline and one-month follow-up visits.
Both groups showed significant reductions in CMT and SRF at one-month follow-up visit. However, there were no statistically significant differences between the IVA and SML groups. Complete SRF resolution was observed in 10 out of 21 and 7 out of 18 eyes in the IVA and SML groups, respectively; however, retinal pigment epithelial (RPE) damage remained persistent in patients with PEDs at baseline.
Both IVA and SML were effective in treating cCSC. IVA and SML treatments had comparable effects in reducing CMT and SRF in eyes with cCSC. Further prospective studies with larger sample sizes and long-term follow-up visits are warranted to identify the long-term efficacy.
cCSC lead to subsequent irreversible photoreceptor damage and visual complaints.IVA and SML treatments have comparable effects in reducing CMT and SRF in cCSC eyes.
摘要：
比较玻璃体腔注射(IVI)联合抗血管内皮生长因子(VEGF)药物阿柏西普(IVA)和亚阈值微脉冲激光(SML)治疗慢性中心性浆液性脉络膜视网膜病变(cCSC)的光学相干断层扫描(OCT)中观察到的短期解剖结果。
■这项回顾性研究中，36例症状性cCSC患者的39只眼在2020年12月至2022年8月期间接受了IVA或SML。在两个治疗组的黄斑中心厚度（CMT）方面，比较了光谱域OCT（SD-OCT）的发现，浆液性视网膜下液（SRF）高度，基线和1个月随访时存在色素上皮脱离(PED)和视网膜下高反射灶(HF).
■两组在1个月的随访中CMT和SRF均显著降低。然而,IVA组和SML组之间的差异无统计学意义.在IVA和SML组中，21只眼中的10只和18只眼中的7只观察到完整的SRF分辨率。分别；然而，基线时,PEDs患者的视网膜色素上皮(RPE)损伤持续存在.
■IVA和SML均可有效治疗cCSC。IVA和SML治疗在降低cCSC眼中的CMT和SRF方面具有相当的效果。需要进行更大样本量和长期随访的进一步前瞻性研究，以确定长期疗效。
cCSC导致随后的不可逆感光体损伤和视觉不适。IVA和SML治疗在降低cCSC眼中的CMT和SRF方面具有相当的效果。
■这项回顾性研究中，36例症状性cCSC患者的39只眼在2020年12月至2022年8月期间接受了IVA或SML。在两个治疗组的黄斑中心厚度（CMT）方面，比较了光谱域OCT（SD-OCT）的发现，浆液性视网膜下液（SRF）高度，基线和1个月随访时存在色素上皮脱离(PED)和视网膜下高反射灶(HF).
■两组在1个月的随访中CMT和SRF均显著降低。然而,IVA组和SML组之间的差异无统计学意义.在IVA和SML组中，21只眼中的10只和18只眼中的7只观察到完整的SRF分辨率。分别；然而，基线时,PEDs患者的视网膜色素上皮(RPE)损伤持续存在.
■IVA和SML均可有效治疗cCSC。IVA和SML治疗在降低cCSC眼中的CMT和SRF方面具有相当的效果。需要进行更大样本量和长期随访的进一步前瞻性研究，以确定长期疗效。
cCSC导致随后的不可逆感光体损伤和视觉不适。IVA和SML治疗在降低cCSC眼中的CMT和SRF方面具有相当的效果。
